Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): A multicenter randomized trial

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2385-2391

  Zhou, Q ^a   Cheng, Y ^b   Yang, J J ^a   Zhao, M F ^c   Zhang, L ^d   Zhang, X C ^a   Chen, Z H ^a   Yan, H H ^a   Song, Y ^e   Chen, J H ^f   Feng, W N ^g   Xu, C R ^a   Wang, Z ^a   Chen, H J ^a   Zhong, W Z ^a   Liu, Y P ^c   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b JILIN PROVINCIAL CANCER HOSPITAL   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d Perking Union Medical Hospital   (China)

^e MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^f HUNAN CANCER HOSPITAL   (China)

^g THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

Chemotherapy; Clinical trial; Non small cell lung cancer; Second line therapy; TKI; Wild type EGFR

Indexed keywords

ALANINE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PEMETREXED; GLUTAMIC ACID DERIVATIVE; GUANINE; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; CHINESE; CONTROLLED STUDY; DIARRHEA; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPERTRANSAMINASEMIA; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; LYMPHOEPITHELIOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84923861432     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu463     Document Type: Article

References (31)

1. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
2. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
3. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
4. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
5. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
6. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-222.
7. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
8. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicenter, open-label, phase 3 study. Lancet Oncol 2012; 13: 300-308.
9. Lee DH, Park K, Kim JH et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16: 1307-1314.
10. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26: 4244-4252.
11. Sun JM, Lee KH, Kim SW et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer 2012; 118: 6234-6242.
12. Karampeazis A, Voutsina A, Souglakos J et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013; 119: 2754-2764.
13. Cufer T, Vrdoljak E, Gaafar R et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006; 17: 401-409.
14. Lee DH, Lee JS, Kim SW et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer 2013; 49: 3111-3121.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. V.4.2014; http://www.nccn.org (10 August 2014, date last accessed).
16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Asia Consensus Statement: Non-small cell lung cancer. V.1.2009; http://www.nccn.org (29 July 2011, date last accessed).
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Chinese V.3.2011; at http://www. nccnchina.org.cn/(22 March 2013, date last accessed).
18. Hayakawa K. Revised by the Japan lung cancer society: guideline for diagnosis and treatment of lung cancer. Gan To Kagaku Ryoho. 2011; 38: 1273-1276.
19. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as secondline treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumors (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14: 981-988.
20. Kawaguchi T, Ando M, Asami K et al. Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902-1908.
21. Zhou Q, Zhang XC, Chen ZH et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 3316-3321.
22. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
23. Chou TY, Chiu CH, Li LH et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 3750-3757.
24. Lee JK, Hahn S, Kim DW et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 2014; 311: 1430-1437.
25. Zhao N, Zhang XC, Yan HH et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-smallcell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer 2014; 85: 66-73.
26. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
27. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
28. Chang A, Parikh P, Thongprasert S et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1: 847-855.
29. Kim ST, Uhm JE, Lee J et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012; 75: 82-88.
30. Katakami N, Morita S, Yoshioka H et al. Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients ( pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. J Clin Oncol 2014; 32(suppl); abstr 8041.
31. Ellison G, Donald E, McWalter G et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010; 29: 132.